Clinical Trial Update: KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update for KeyLargo combining pembrolizumab with oxaliplatin and capecitabine in gastric and esophageal cancer; study completed with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Duke University | Conditions: Gastric Cancer, Esophagus Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-03-13